Sweis I, Cressey B
Plast Reconstr Surg Glob Open. 2024; 12(11):e6340.
PMID: 39583781
PMC: 11584228.
DOI: 10.1097/GOX.0000000000006340.
Durmus Ece B, Yozgat Z, Bayramli H, Ece B, Aydin S
J Clin Med. 2024; 13(19).
PMID: 39407871
PMC: 11478186.
DOI: 10.3390/jcm13195808.
Zeppieri M, Gagliano C, Spadea L, Salati C, Chukwuyem E, Enaholo E
Pharmaceuticals (Basel). 2024; 17(5).
PMID: 38794131
PMC: 11124470.
DOI: 10.3390/ph17050561.
Boubertakh B, Courtemanche O, Marsolais D, Di Marzo V, Silvestri C
J Lipid Res. 2023; 64(11):100444.
PMID: 37730163
PMC: 10622703.
DOI: 10.1016/j.jlr.2023.100444.
Abalo-Lojo J, Vazquez Ferreiro P, Asorey M, Colmenero A, Gonzalez F
Turk J Ophthalmol. 2023; 53(1):8-12.
PMID: 36847619
PMC: 9973213.
DOI: 10.4274/tjo.galenos.2022.24365.
Addition of ROCK Inhibitors Alleviates Prostaglandin-Induced Inhibition of Adipogenesis in 3T3L-1 Spheroids.
Ida Y, Sato T, Umetsu A, Watanabe M, Furuhashi M, Hikage F
Bioengineering (Basel). 2022; 9(11).
PMID: 36421103
PMC: 9687287.
DOI: 10.3390/bioengineering9110702.
Brimonidine Modulates the ROCK1 Signaling Effects on Adipogenic Differentiation in 2D and 3D 3T3-L1 Cells.
Umetsu A, Ida Y, Sato T, Watanabe M, Tsugeno Y, Furuhashi M
Bioengineering (Basel). 2022; 9(7).
PMID: 35877378
PMC: 9311963.
DOI: 10.3390/bioengineering9070327.
Prostaglandin F2 and EP2 Agonists Exert Different Effects on 3D 3T3-L1 Spheroids during Their Culture Phase.
Ida Y, Furuhashi M, Watanabe M, Umetsu A, Hikage F, Ohguro H
Biomedicines. 2021; 9(12).
PMID: 34944637
PMC: 8698783.
DOI: 10.3390/biomedicines9121821.
Prostanoid receptor agonists for glaucoma treatment.
Aihara M
Jpn J Ophthalmol. 2021; 65(5):581-590.
PMID: 34228229
DOI: 10.1007/s10384-021-00844-6.
Omidenepag, a Selective, Prostanoid EP2 Agonist, Does Not Suppress Adipogenesis in 3D Organoids of Human Orbital Fibroblasts.
Hikage F, Ida Y, Ouchi Y, Watanabe M, Ohguro H
Transl Vis Sci Technol. 2021; 10(4):6.
PMID: 34003984
PMC: 8039573.
DOI: 10.1167/tvst.10.4.6.
Prostaglandin F2α agonists induced enhancement in collagen1 expression is involved in the pathogenesis of the deepening of upper eyelid sulcus.
Itoh K, Ida Y, Ohguro H, Hikage F
Sci Rep. 2021; 11(1):9002.
PMID: 33903711
PMC: 8076191.
DOI: 10.1038/s41598-021-88562-4.
Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells.
Ida Y, Hikage F, Umetsu A, Ida H, Ohguro H
Sci Rep. 2020; 10(1):16018.
PMID: 32994409
PMC: 7524797.
DOI: 10.1038/s41598-020-72538-x.
Distribution of C-Latanoprost Following a Single Intracameral Administration Versus Repeated Topical Administration.
Shen J, Moats R, Pollack H, Robinson M, Attar M
Ophthalmol Ther. 2020; 9(4):929-940.
PMID: 32740740
PMC: 7708611.
DOI: 10.1007/s40123-020-00285-3.
Prostaglandin F2α Agonists Negatively Modulate the Size of 3D Organoids from Primary Human Orbital Fibroblasts.
Itoh K, Hikage F, Ida Y, Ohguro H
Invest Ophthalmol Vis Sci. 2020; 61(6):13.
PMID: 32503053
PMC: 7415291.
DOI: 10.1167/iovs.61.6.13.
Orbital Fat Volume After Treatment with Topical Prostaglandin Agonists.
Chen J, Le A, Caprioli J, Giaconi J, Nouri-Mahdavi K, Law S
Invest Ophthalmol Vis Sci. 2020; 61(5):46.
PMID: 32455434
PMC: 7405708.
DOI: 10.1167/iovs.61.5.46.
Prostaglandin F2α agonist-induced suppression of 3T3-L1 cell adipogenesis affects spatial formation of extra-cellular matrix.
Ida Y, Hikage F, Itoh K, Ida H, Ohguro H
Sci Rep. 2020; 10(1):7958.
PMID: 32409724
PMC: 7224398.
DOI: 10.1038/s41598-020-64674-1.
Optic Nerve Traction During Adduction in Open Angle Glaucoma with Normal versus Elevated Intraocular Pressure.
Demer J, Clark R, Suh S, Giaconi J, Nouri-Mahdavi K, Law S
Curr Eye Res. 2019; 45(2):199-210.
PMID: 31453714
PMC: 7398593.
DOI: 10.1080/02713683.2019.1660371.
Decreased orbital fat and enophthalmos due to bimatoprost: Quantitative analysis using magnetic resonance imaging.
Higashiyama T, Minamikawa T, Kakinoki M, Sawada O, Ohji M
PLoS One. 2019; 14(3):e0214065.
PMID: 30917168
PMC: 6436740.
DOI: 10.1371/journal.pone.0214065.
Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy.
Higashiyama T, Ohji M
Clin Ophthalmol. 2018; 12:2415-2421.
PMID: 30568419
PMC: 6267500.
DOI: 10.2147/OPTH.S187164.
Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations.
Shen J, Lu G, Hughes P
Pharm Res. 2018; 35(11):217.
PMID: 30255364
DOI: 10.1007/s11095-018-2498-y.